Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients

Bibliography

• Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28:958-66
   PubMed Web of Science ®Google Scholar
• Ebbesson SO, Risica PM, Ebbesson LO, et al. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int J Circumpolar Health 2005;64:396-408
   PubMedGoogle Scholar
• Skerrett PJ, Hennekens CH. Consumption of fish and fish oils and decreased risk of stroke. Prev Cardiol 2003;1:38-41
   Google Scholar
• Mozaffarian D, Longstreth WT Jr, Lemaitre RN, et al. Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. Arch Intern Med 2005;165:200-6
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Tangney CC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005;62:1849-53
   PubMedGoogle Scholar
• Brouwer IA, Heeringa J, Geleijnse JM, et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006;151:857-62
   PubMed Web of Science ®Google Scholar
• Gissi-Hf Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30
   PubMed Web of Science ®Google Scholar
• Borghi C, Cicero AFG. Blood pressure modulating properties of Omega-3 polyunsaturated fatty acids (PUFA). Another PUFA heart protective effect? High Blood Press Cardiov Prev 2007;14(2):1-7
   Google Scholar
• Matsumoto M, Sata M, Fukuda D, et al. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2008;197(2):524-33
   PubMed Web of Science ®Google Scholar
• Delbosc S, Glorian M, Le Port AS, et al. The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am J Pathol 2008;172(5):1430-40
   PubMedGoogle Scholar
• Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361(9356):477-85
   PubMed Web of Science ®Google Scholar
• International Lipid Information Bureau. Third edition. The ILIB lipid handbook for clinical practice: Dyslipidemia and coronary heart disease. New York, 2003. p. 1-242
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9
   PubMed Web of Science ®Google Scholar
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 1999;16:716-30
   PubMed Web of Science ®Google Scholar
• Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
   PubMed Web of Science ®Google Scholar
• Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-30
   Google Scholar
• Wahlefeld AW. Second English edititon. Methods of enzymatic analysis: Triglycerides determination after enzymatic hydrolysis, Academic Press, Inc., New York, 1974. p. 18-31
   Google Scholar
• Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992;2:427-38
   PubMedGoogle Scholar
• Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1959;17:237-46
   Google Scholar
• Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. J Chromatography 1987;422:43-52
   PubMed Web of Science ®Google Scholar
• Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45(12):2136-41
   PubMed Web of Science ®Google Scholar
• Scanu AM, Scandian L. Lipoprotein (a): structure, biology and clinical relevance. Adv Intern Med 1991;36:249-70
   PubMedGoogle Scholar
• Uterman G, Weber W. Protein composition of lipoprotein (a). J Clin Invest 1987;80:458-65
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Mouri N, Iwata K, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993;221(1-2):91-103
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Hosokawa N, Iwata K, et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994;231(1):79-88
   PubMed Web of Science ®Google Scholar
• Clark IM, Powell LK, Wright JK, Cawston TE. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991;11(2):76-85
   PubMedGoogle Scholar
• Fujimoto N, Zhang J, Iwata K, et al. A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta 1993;220(1):31-45
   PubMed Web of Science ®Google Scholar
• Winer BJ. Statistical principles in experimental design, Second edition. McGraw-Hill New York, 1971
   Google Scholar
• Sierevogel MJ, Pasterkamp G, de Kleijn DP, Strauss BH. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003;9(13):1033-40
   PubMed Web of Science ®Google Scholar
• Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003;26(2):55-9
   PubMed Web of Science ®Google Scholar
• Inokubo Y, Hanada H, Ishizaka H, et al. Plasma level of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-7
   PubMed Web of Science ®Google Scholar
• Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Scalise F, et al. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 2007;14(1):45-51
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Scalise F, et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007;22(6):361-70
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006;13(3):227-31
   PubMed Web of Science ®Google Scholar
• Derosa G, Avanzini MA, Geroldi D, et al. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005;70(2):119-25
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007;33(2):129-34
   PubMed Web of Science ®Google Scholar
• Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008;15(4):219-24
   PubMed Web of Science ®Google Scholar
• Cicero AF, Derosa G, Manca M, et al. Vascular remodelling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 2007;14(4-5):193-8
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, D'Angelo A, et al. Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy. High Blood Press Cardiov Prev 2006;13(2):47-52
   Google Scholar
• Lee JH, O'keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83(3):324-32
   PubMed Web of Science ®Google Scholar
• Furenes EB, Seljeflot I, Solheim S, et al. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand J Clin Lab Invest 2008;68(3):177-84
   PubMed Web of Science ®Google Scholar
• Aarsetøy H, Brügger-Andersen T, Hetland Ø, et al. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006;95(2):329-36
   PubMedGoogle Scholar
• Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-9
   PubMed Web of Science ®Google Scholar
• Cheng M, Hashmi S, Mao X, Zeng QT. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008;24(5):385-90
   PubMed Web of Science ®Google Scholar
• Neschen S, Morino K, Dong J, et al. n-3 Fatty Acids preserve insulin sensitivity in vivo in a peroxisome proliferator–activated receptor-α–dependent manner. Diabetes 2007;56:1034-41
   PubMedGoogle Scholar
• Winzell MS, Pacini G, Ahre′n B. Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice. Am J Physiol Endocrinol Metab 2006;290:347-54
   Google Scholar
• Morvarid K, Skurnik G, Naour N, et al. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007;86:1670-9
   PubMedGoogle Scholar
• Neschen S, Morino K, Rossbacher JC, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006;55:924-8
   PubMed Web of Science ®Google Scholar
• Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006;49:394-7
   PubMed Web of Science ®Google Scholar
• Rodríguez-Cruz M, Tovar AR, del Prado M, Torres N. Molecular mechanisms of action and health benefits of polyunsaturated fatty acids. Rev Invest Clin 2005;57(3):457-72
   PubMedGoogle Scholar